Achyut Bhagelu R, Varma Nadimpalli Ravi S, Arbab Ali S
Tumor Angiogenesis Lab, Cancer Center, Georgia Regents University, Augusta, GA 30912, USA.
Cellular and Molecular Imaging Laboratory, Henry Ford Hospital, Detroit, MI 48202.
J Stem Cell Res Ther. 2014;4. doi: 10.4172/2157-7633.1000202.
Umbilical cord blood (UCB) derived multipotent stem cells are capable of giving rise hematopoietic, epithelial, endothelial and neural progenitor cells. Thus suggested to significantly improve graft-versus-host disease and represent the distinctive therapeutic option for several malignant and non-malignant diseases. Recent advances in strategies to isolate, expand and shorten the timing of UCB stem cells engraftment have tremendously improved the efficacy of transplantations. Nervous system has limited regenerative potential in disease conditions such as cancer, neurodegeneration, stroke, and several neural injuries. This review focuses on application of UCB derived stem/progenitor cells in aforementioned pathological conditions. We have discussed the possible attempts to make use of UCB therapies to generate neural cells and tissues with developmental and functional similarities to neuronal cells. In addition, emerging applications of UCB derived AC133+ (CD133+) endothelial progenitor cells (EPCs) as imaging probe, regenerative agent, and gene delivery vehicle are mentioned that will further improve the understanding of use of UCB cells in therapeutic modalities. However, safe and effective protocols for cell transplantations are still required for therapeutic efficacy.
脐带血（UCB）来源的多能干细胞能够分化产生造血、上皮、内皮和神经祖细胞。因此，它被认为能显著改善移植物抗宿主病，并成为多种恶性和非恶性疾病独特的治疗选择。在分离、扩增和缩短脐带血干细胞植入时间的策略方面，最近的进展极大地提高了移植的疗效。在癌症、神经退行性疾病、中风和一些神经损伤等疾病状态下，神经系统的再生潜力有限。本综述重点关注脐带血来源的干细胞/祖细胞在上述病理状况中的应用。我们讨论了利用脐带血疗法生成与神经元细胞具有发育和功能相似性的神经细胞和组织的可能尝试。此外，还提到了脐带血来源的AC133 +（CD133 +）内皮祖细胞（EPCs）作为成像探针、再生剂和基因传递载体的新兴应用，这将进一步增进对脐带血细胞在治疗方式中应用的理解。然而，为了达到治疗效果，仍需要安全有效的细胞移植方案。
